Ankylosing Spondylitis Market by Drug Type (Nonsteroidal Anti-Inflammatory Drugs, TNF blockers, Immunosuppressive Drugs, Anti-Inflammatory Drugs, Steroids, JAK Inhibitors, Others (IL-17 Inhibitors); by Application (Juveniles, Adults); by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2018 - 2026
Industry Trends
Ankylosing Spondylitis (AS) is a common chronic inflammatory rheumatic disease, which are seen in young adults, often in their late teens or early twenties. It can cause pain in lower back and neck. Over the time, AS can cause spine to become curved and rigid and affecting the shape of spine. Normally AS causes pain in spine but in some cases AS can cause swelling and pain in heels, chest, hips and shoulders. Early diagnosis is crucial in ankylosing spondylitis as spinal deformity can be minimized with the help of proper treatment.
Management of ankylosing spondylitis can be done with pharmacological and nonpharmacological treatments. Pharmacological treatments are limited but however researchers are working on innovations in biological drugs and improvements of the treatment in this field. These treatments involve preservation of physical function, control of inflammation and symptoms and stoppage of progressive structural damage and disabilities. In pharmacological treatments, non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies. In many studies it has been observed that, NSAIDs provide great and rapid relief to inflammatory back pain. However, with this treatment, several rebound symptoms such as stiffness, swelling and joint pain can be observed after few days. Nonpharmacological treatments for ankylosing spondylitis involves regular exercise and patient training. It has been observed that these treatments are helpful in enhancement of spinal mobility parameters however they have not affected disease activity.
The ankylosing spondylitis market, in terms of revenue, was valued at US$ 5.34 Bn in 2017 and is expected to reach US$ 6.84 Bn by 2022.
Global Ankylosing Spondylitis Market, By Application, 2017 & 2022 (USD Billion)
There is no cure for AS, but have several approved treatments to manage the symptoms, such as anti-inflammatory drugs, over-the-counter pain relievers, prescription medicines, as well as exercise program. Many research institutes are working on various therapy and diagnosis of ankylosing spondylitis. Radiographic studies are also helpful in the detection, diagnosis and monitoring of AS patients. Also, computed tomography can be used in some selected situations such as bone formations at various sites, sclerotic changes and erosions.
Poor prognosis for cure of ankylosing spondylitis can critically impact the ankylosing spondylitis market. As per NIAMS, AS generally occurs at young age often before 30s. The symptoms start with stiffness and pain which develops slowly over the week or months. Correct diagnosis and treatment can help to recover the symptoms which can slow down the development of disease.
Non-steroidal anti-inflammatory drugs (NSAIDs) can help to reduce the symptoms and signs of axial movements with spondyloarthropathies. In many studies it has been observed that, NSAIDs provide great and rapid relief in inflammatory back pain. There are some rebound symptoms such as stiffness, swelling and joint pain that can be observed after few days.
Ankylosing Spondylitis Market, by Region
Asia Pacific region represents a lot of opportunities for future growth in the market. The organizations and institutes in this region are investing heavily in R&D as there are not any approved treatments available for this disease. For instance, Novartis Pharmaceuticals in Japan is currently carrying clinical trial on patients for clinical efficacy and safety of secukinumab subcutaneous injections for the treatment of ankylosing spondylitis. The study was started in April 2016 and expected to complete in November 2018.
Competitive Market Share
The ankylosing spondylitis market report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions(M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.
Key participants of global ankylosing spondylitis market are AbbVie Inc, Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., Sanofi Aventis, CELGENE Corporation, Celltrion Healthcare Co., Ltd., Eisai Co., Ltd., Galapagos NV, Protalix Ltd., Regeneron Pharmaceuticals, Inc., Shanghai Pharmaceuticals Holding Co., Ltd, UCB S.A., and Xian Janssen Pharmaceutical Ltd amongst others.
Ankylosing Spondylitis Industry Background
1. Introduction
1.1. Market Scope
1.2. Market Segmentation
1.3. Methodology
1.4. Assumptions
2. Ankylosing Spondylitis Market Snapshot
3. Executive Summary: Ankylosing Spondylitis Market
4. Qualitative Analysis: Ankylosing Spondylitis Market
4.1. Introduction
4.1.1. Product Definition
4.1.2. Industry Development
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Trends in Market
5. Global Ankylosing Spondylitis Market Analysis and Forecasts,
2018 – 2026
5.1. Overview
5.1.1. Global Market Revenue (US$ Mn) and Forecasts
5.2. Global Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
5.2.1. Nonsteroidal Anti-Inflammatory Drugs
5.2.1.1. Definition
5.2.1.2. Market Penetration
5.2.1.3. Market Revenue Expected to Increase by 2026
5.2.1.4. Compound Annual Growth Rate (CAGR)
5.2.2. TNF blockers
5.2.2.1. Definition
5.2.2.2. Market Penetration
5.2.2.3. Market Revenue Expected to Increase by 2026
5.2.2.4. Compound Annual Growth Rate (CAGR)
5.2.3. Immunosuppressive Drugs
5.2.3.1. Definition
5.2.3.2. Market Penetration
5.2.3.3. Market Revenue Expected to Increase by 2026
5.2.3.4. Compound Annual Growth Rate (CAGR)
5.2.4. Anti-Inflammatory Drugs
5.2.4.1. Definition
5.2.4.2. Market Penetration
5.2.4.3. Market Revenue Expected to Increase by 2026
5.2.4.4. Compound Annual Growth Rate (CAGR)
5.2.5. Steroids
5.2.5.1. Definition
5.2.5.2. Market Penetration
5.2.5.3. Market Revenue Expected to Increase by 2026
5.2.5.4. Compound Annual Growth Rate (CAGR)
5.2.6. JAK Inhibitors
5.2.6.1. Definition
5.2.6.2. Market Penetration
5.2.6.3. Market Revenue Expected to Increase by 2026
5.2.6.4. Compound Annual Growth Rate (CAGR)
5.2.7. Others (IL-17 Inhibitors)
5.2.7.1. Definition
5.2.7.2. Market Penetration
5.2.7.3. Market Revenue Expected to Increase by 2026
5.2.7.4. Compound Annual Growth Rate (CAGR)
5.3. Key Segment for Channeling Investments
5.3.1. By Drug Type
6. Global Ankylosing Spondylitis Market Analysis and Forecasts,
2018 – 2026
6.1. Overview
6.2. Global Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
6.2.1. Juveniles
6.2.1.1. Definition
6.2.1.2. Market Penetration
6.2.1.3. Market Revenue Expected to Increase by 2026
6.2.1.4. Compound Annual Growth Rate (CAGR)
6.2.2. Adults
6.2.2.1. Definition
6.2.2.2. Market Penetration
6.2.2.3. Market Revenue Expected to Increase by 2026
6.2.2.4. Compound Annual Growth Rate (CAGR)
6.3. Key Segment for Channeling Investments
6.3.1. By Application
7. North America Ankylosing Spondylitis Market Analysis and
Forecasts, 2018 – 2026
7.1. Overview
7.1.1. North America Market Revenue (US$ Mn)
7.2. North America Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
7.2.1. Nonsteroidal Anti-Inflammatory Drugs
7.2.2. TNF blockers
7.2.3. Immunosuppressive Drugs
7.2.4. Anti-Inflammatory Drugs
7.2.5. Steroids
7.2.6. JAK Inhibitors
7.2.7. Others (IL-17 Inhibitors)
7.3. North America Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
7.3.1. Juveniles
7.3.2. Adults
7.4. North America Market Revenue (US$ Mn) and Forecasts, By
Country
7.4.1. U.S.
7.4.1.1. U.S. Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
7.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs
7.4.1.1.2. TNF blockers
7.4.1.1.3. Immunosuppressive Drugs
7.4.1.1.4. Anti-Inflammatory Drugs
7.4.1.1.5. Steroids
7.4.1.1.6. JAK Inhibitors
7.4.1.1.7. Others (IL-17 Inhibitors)
7.4.1.2. U.S. Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
7.4.1.2.1. Juveniles
7.4.1.2.2. Adults
7.4.2. Rest of North America
7.4.2.1. Rest of North America Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Drug Type
7.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
7.4.2.1.2. TNF blockers
7.4.2.1.3. Immunosuppressive Drugs
7.4.2.1.4. Anti-Inflammatory Drugs
7.4.2.1.5. Steroids
7.4.2.1.6. JAK Inhibitors
7.4.2.1.7. Others (IL-17 Inhibitors)
7.4.2.2. Rest of North America Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Application
7.4.2.2.1. Juveniles
7.4.2.2.2. Adults
7.5. Key Segment for Channeling Investments
7.5.1. By Country
7.5.2. By Drug Type
7.5.3. By Application
8. Europe Ankylosing Spondylitis Market Analysis and Forecasts,
2018 – 2026
8.1. Overview
8.1.1. Europe Market Revenue (US$ Mn)
8.2. Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.2.1. Nonsteroidal Anti-Inflammatory Drugs
8.2.2. TNF blockers
8.2.3. Immunosuppressive Drugs
8.2.4. Anti-Inflammatory Drugs
8.2.5. Steroids
8.2.6. JAK Inhibitors
8.2.7. Others (IL-17 Inhibitors)
8.3. Europe Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.3.1. Juveniles
8.3.2. Adults
8.4. Europe Market Revenue (US$ Mn) and Forecasts, By Country
8.4.1. France
8.4.1.1. France Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.1.1.2. TNF blockers
8.4.1.1.3. Immunosuppressive Drugs
8.4.1.1.4. Anti-Inflammatory Drugs
8.4.1.1.5. Steroids
8.4.1.1.6. JAK Inhibitors
8.4.1.1.7. Others (IL-17 Inhibitors)
8.4.1.2. France Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.4.1.2.1. Juveniles
8.4.1.2.2. Adults
8.4.2. The UK
8.4.2.1. The UK Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.2.1.2. TNF blockers
8.4.2.1.3. Immunosuppressive Drugs
8.4.2.1.4. Anti-Inflammatory Drugs
8.4.2.1.5. Steroids
8.4.2.1.6. JAK Inhibitors
8.4.2.1.7. Others (IL-17 Inhibitors)
8.4.2.2. The UK Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.4.2.2.1. Juveniles
8.4.2.2.2. Adults
8.4.3. Spain
8.4.3.1. Spain Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.4.3.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.3.1.2. TNF blockers
8.4.3.1.3. Immunosuppressive Drugs
8.4.3.1.4. Anti-Inflammatory Drugs
8.4.3.1.5. Steroids
8.4.3.1.6. JAK Inhibitors
8.4.3.1.7. Others (IL-17 Inhibitors)
8.4.3.2. Spain Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.4.3.2.1. Juveniles
8.4.3.2.2. Adults
8.4.4. Germany
8.4.4.1. Germany Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.4.4.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.4.1.2. TNF blockers
8.4.4.1.3. Immunosuppressive Drugs
8.4.4.1.4. Anti-Inflammatory Drugs
8.4.4.1.5. Steroids
8.4.4.1.6. JAK Inhibitors
8.4.4.1.7. Others (IL-17 Inhibitors)
8.4.4.2. Germany Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.4.4.2.1. Juveniles
8.4.4.2.2. Adults
8.4.5. Italy
8.4.5.1. Italy Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
8.4.5.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.5.1.2. TNF blockers
8.4.5.1.3. Immunosuppressive Drugs
8.4.5.1.4. Anti-Inflammatory Drugs
8.4.5.1.5. Steroids
8.4.5.1.6. JAK Inhibitors
8.4.5.1.7. Others (IL-17 Inhibitors)
8.4.5.2. Italy Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
8.4.5.2.1. Juveniles
8.4.5.2.2. Adults
8.4.6. Rest of Europe
8.4.6.1. Rest of Europe Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
8.4.6.1.1. Nonsteroidal Anti-Inflammatory Drugs
8.4.6.1.2. TNF blockers
8.4.6.1.3. Immunosuppressive Drugs
8.4.6.1.4. Anti-Inflammatory Drugs
8.4.6.1.5. Steroids
8.4.6.1.6. JAK Inhibitors
8.4.6.1.7. Others (IL-17 Inhibitors)
8.4.6.2. Rest of Europe Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
8.4.6.2.1. Juveniles
8.4.6.2.2. Adults
8.5. Key Segment for Channeling Investments
8.5.1. By Country
8.5.2. By Drug Type
8.5.3. By Application
9. Asia Pacific Ankylosing Spondylitis Market Analysis and
Forecasts, 2018 – 2026
9.1. Overview
9.1.1. Asia Pacific Market Revenue (US$ Mn)
9.2. Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
9.2.1. Nonsteroidal Anti-Inflammatory Drugs
9.2.2. TNF blockers
9.2.3. Immunosuppressive Drugs
9.2.4. Anti-Inflammatory Drugs
9.2.5. Steroids
9.2.6. JAK Inhibitors
9.2.7. Others (IL-17 Inhibitors)
9.3. Asia Pacific Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
9.3.1. Juveniles
9.3.2. Adults
9.4. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Country
9.4.1. China
9.4.1.1. China Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
9.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs
9.4.1.1.2. TNF blockers
9.4.1.1.3. Immunosuppressive Drugs
9.4.1.1.4. Anti-Inflammatory Drugs
9.4.1.1.5. Steroids
9.4.1.1.6. JAK Inhibitors
9.4.1.1.7. Others (IL-17 Inhibitors)
9.4.1.2. China Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
9.4.1.2.1. Juveniles
9.4.1.2.2. Adults
9.4.2. Japan
9.4.2.1. Japan Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
9.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
9.4.2.1.2. TNF blockers
9.4.2.1.3. Immunosuppressive Drugs
9.4.2.1.4. Anti-Inflammatory Drugs
9.4.2.1.5. Steroids
9.4.2.1.6. JAK Inhibitors
9.4.2.1.7. Others (IL-17 Inhibitors)
9.4.2.2. Japan Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
9.4.2.2.1. Juveniles
9.4.2.2.2. Adults
9.4.3. India
9.4.3.1. India Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
9.4.3.1.1. Nonsteroidal Anti-Inflammatory Drugs
9.4.3.1.2. TNF blockers
9.4.3.1.3. Immunosuppressive Drugs
9.4.3.1.4. Anti-Inflammatory Drugs
9.4.3.1.5. Steroids
9.4.3.1.6. JAK Inhibitors
9.4.3.1.7. Others (IL-17 Inhibitors)
9.4.3.2. India Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
9.4.3.2.1. Juveniles
9.4.3.2.2. Adults
9.4.4. Southeast Asia
9.4.4.1. Southeast Asia Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
9.4.4.1.1. Nonsteroidal Anti-Inflammatory Drugs
9.4.4.1.2. TNF blockers
9.4.4.1.3. Immunosuppressive Drugs
9.4.4.1.4. Anti-Inflammatory Drugs
9.4.4.1.5. Steroids
9.4.4.1.6. JAK Inhibitors
9.4.4.1.7. Others (IL-17 Inhibitors)
9.4.4.2. Southeast Asia Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
9.4.4.2.1. Juveniles
9.4.4.2.2. Adults
9.4.5. Rest of Asia Pacific
9.4.5.1. Rest of Asia Pacific Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Drug Type
9.4.5.1.1. Nonsteroidal Anti-Inflammatory Drugs
9.4.5.1.2. TNF blockers
9.4.5.1.3. Immunosuppressive Drugs
9.4.5.1.4. Anti-Inflammatory Drugs
9.4.5.1.5. Steroids
9.4.5.1.6. JAK Inhibitors
9.4.5.1.7. Others (IL-17 Inhibitors)
9.4.5.2. Rest of Asia Pacific Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Application
9.4.5.2.1. Juveniles
9.4.5.2.2. Adults
9.5. Key Segment for Channeling Investments
9.5.1. By Country
9.5.2. By Drug Type
9.5.3. By Application
10. Middle East and Africa Ankylosing Spondylitis Market Analysis
and Forecasts, 2018 – 2026
10.1. Overview
10.1.1. Middle East and Africa Market Revenue (US$ Mn)
10.2. Middle East and Africa Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Drug Type
10.2.1. Nonsteroidal Anti-Inflammatory Drugs
10.2.2. TNF blockers
10.2.3. Immunosuppressive Drugs
10.2.4. Anti-Inflammatory Drugs
10.2.5. Steroids
10.2.6. JAK Inhibitors
10.2.7. Others (IL-17 Inhibitors)
10.3. Middle East and Africa Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Application
10.3.1. Juveniles
10.3.2. Adults
10.4. Middle East and Africa Market Revenue (US$ Mn) and Forecasts,
By Country
10.4.1. GCC Countries
10.4.1.1. GCC Countries Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
10.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs
10.4.1.1.2. TNF blockers
10.4.1.1.3. Immunosuppressive Drugs
10.4.1.1.4. Anti-Inflammatory Drugs
10.4.1.1.5. Steroids
10.4.1.1.6. JAK Inhibitors
10.4.1.1.7. Others (IL-17 Inhibitors)
10.4.1.2. GCC Countries Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
10.4.1.2.1. Juveniles
10.4.1.2.2. Adults
10.4.2. Southern Africa
10.4.2.1. Southern Africa Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
10.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
10.4.2.1.2. TNF blockers
10.4.2.1.3. Immunosuppressive Drugs
10.4.2.1.4. Anti-Inflammatory Drugs
10.4.2.1.5. Steroids
10.4.2.1.6. JAK Inhibitors
10.4.2.1.7. Others (IL-17 Inhibitors)
10.4.2.2. Southern Africa Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
10.4.2.2.1. Juveniles
10.4.2.2.2. Adults
10.4.3. Rest of MEA
10.4.3.1. Rest of MEA Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
10.4.3.1.1. Nonsteroidal Anti-Inflammatory Drugs
10.4.3.1.2. TNF blockers
10.4.3.1.3. Immunosuppressive Drugs
10.4.3.1.4. Anti-Inflammatory Drugs
10.4.3.1.5. Steroids
10.4.3.1.6. JAK Inhibitors
10.4.3.1.7. Others (IL-17 Inhibitors)
10.4.3.2. Rest of MEA Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
10.4.3.2.1. Juveniles
10.4.3.2.2. Adults
10.5. Key Segment for Channeling Investments
10.5.1. By Country
10.5.2. By Drug Type
10.5.3. By Application
11. Latin America Ankylosing Spondylitis Market Analysis and
Forecasts, 2018 – 2026
11.1. Overview
11.1.1. Latin America Market Revenue (US$ Mn)
11.2. Latin America Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Drug Type
11.2.1. Nonsteroidal Anti-Inflammatory Drugs
11.2.2. TNF blockers
11.2.3. Immunosuppressive Drugs
11.2.4. Anti-Inflammatory Drugs
11.2.5. Steroids
11.2.6. JAK Inhibitors
11.2.7. Others (IL-17 Inhibitors)
11.3. Latin America Ankylosing Spondylitis Market Revenue (US$ Mn)
and Forecasts, By Application
11.3.1. Juveniles
11.3.2. Adults
11.4. Latin America Market Revenue (US$ Mn) and Forecasts, By
Country
11.4.1. Brazil
11.4.1.1. Brazil Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Drug Type
11.4.1.1.1. Nonsteroidal Anti-Inflammatory Drugs
11.4.1.1.2. TNF blockers
11.4.1.1.3. Immunosuppressive Drugs
11.4.1.1.4. Anti-Inflammatory Drugs
11.4.1.1.5. Steroids
11.4.1.1.6. JAK Inhibitors
11.4.1.1.7. Others (IL-17 Inhibitors)
11.4.1.2. Brazil Ankylosing Spondylitis Market Revenue (US$ Mn) and
Forecasts, By Application
11.4.1.2.1. Juveniles
11.4.1.2.2. Adults
11.4.2. Rest of Latin America
11.4.2.1. Rest of Latin America Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Drug Type
11.4.2.1.1. Nonsteroidal Anti-Inflammatory Drugs
11.4.2.1.2. TNF blockers
11.4.2.1.3. Immunosuppressive Drugs
11.4.2.1.4. Anti-Inflammatory Drugs
11.4.2.1.5. Steroids
11.4.2.1.6. JAK Inhibitors
11.4.2.1.7. Others (IL-17 Inhibitors)
11.4.2.2. Rest of Latin America Ankylosing Spondylitis Market Revenue
(US$ Mn) and Forecasts, By Application
11.4.2.2.1. Juveniles
11.4.2.2.2. Adults
11.5. Key Segment for Channeling Investments
11.5.1. By Country
11.5.2. By Drug Type
11.5.3. By Application
12. Competitive Benchmarking
12.1. Player Positioning Analysis
12.2. Global Presence and Growth Strategies
13. Player Profiles
13.1. AbbVie Inc
13.1.1. Company Details
13.1.2. Company Overview
13.1.3. Product Offerings
13.1.4. Key Developments
13.1.5. Financial Analysis
13.1.6. SWOT Analysis
13.1.7. Business Strategies
13.2. Amgen Inc.
13.2.1. Company Details
13.2.2. Company Overview
13.2.3. Product Offerings
13.2.4. Key Developments
13.2.5. Financial Analysis
13.2.6. SWOT Analysis
13.2.7. Business Strategies
13.3. Bristol-Myers Squibb Company
13.3.1. Company Details
13.3.2. Company Overview
13.3.3. Product Offerings
13.3.4. Key Developments
13.3.5. Financial Analysis
13.3.6. SWOT Analysis
13.3.7. Business Strategies
13.4. F. Hoffmann-La Roche Ltd.,
13.4.1. Company Details
13.4.2. Company Overview
13.4.3. Product Offerings
13.4.4. Key Developments
13.4.5. Financial Analysis
13.4.6. SWOT Analysis
13.4.7. Business Strategies
13.5. Merck & Co., Inc.,
13.5.1. Company Details
13.5.2. Company Overview
13.5.3. Product Offerings
13.5.4. Key Developments
13.5.5. Financial Analysis
13.5.6. SWOT Analysis
13.5.7. Business Strategies
13.6. Novartis AG
13.6.1. Company Details
13.6.2. Company Overview
13.6.3. Product Offerings
13.6.4. Key Developments
13.6.5. Financial Analysis
13.6.6. SWOT Analysis
13.6.7. Business Strategies
13.7. Pfizer Inc.
13.7.1. Company Details
13.7.2. Company Overview
13.7.3. Product Offerings
13.7.4. Key Developments
13.7.5. Financial Analysis
13.7.6. SWOT Analysis
13.7.7. Business Strategies
13.8. Sanofi Aventis
13.8.1. Company Details
13.8.2. Company Overview
13.8.3. Product Offerings
13.8.4. Key Developments
13.8.5. Financial Analysis
13.8.6. SWOT Analysis
13.8.7. Business Strategies
13.9. CELGENE Corporation
13.9.1. Company Details
13.9.2. Company Overview
13.9.3. Product Offerings
13.9.4. Key Developments
13.9.5. Financial Analysis
13.9.6. SWOT Analysis
13.9.7. Business Strategies
13.10. Celltrion Healthcare Co., Ltd.,
13.10.1.
Company Details
13.10.2.
Company Overview
13.10.3.
Product Offerings
13.10.4.
Key Developments
13.10.5.
Financial Analysis
13.10.6.
SWOT Analysis
13.10.7.
Business Strategies
13.11. Eisai Co., Ltd
13.11.1.
Company Details
13.11.2.
Company Overview
13.11.3.
Product Offerings
13.11.4.
Key Developments
13.11.5.
Financial Analysis
13.11.6.
SWOT Analysis
13.11.7.
Business Strategies
13.12. Galapagos NV
13.12.1.
Company Details
13.12.2.
Company Overview
13.12.3.
Product Offerings
13.12.4.
Key Developments
13.12.5.
Financial Analysis
13.12.6.
SWOT Analysis
13.12.7.
Business Strategies
13.13. Protalix Ltd.,
13.13.1.
Company Details
13.13.2.
Company Overview
13.13.3.
Product Offerings
13.13.4.
Key Developments
13.13.5.
Financial Analysis
13.13.6.
SWOT Analysis
13.13.7.
Business Strategies
13.14. Regeneron Pharmaceuticals, Inc.
13.14.1.
Company Details
13.14.2.
Company Overview
13.14.3.
Product Offerings
13.14.4.
Key Developments
13.14.5.
Financial Analysis
13.14.6.
SWOT Analysis
13.14.7.
Business Strategies
13.15. Shanghai Pharmaceuticals Holding Co., Ltd
13.15.1.
Company Details
13.15.2.
Company Overview
13.15.3.
Product Offerings
13.15.4.
Key Developments
13.15.5.
Financial Analysis
13.15.6.
SWOT Analysis
13.15.7.
Business Strategies
13.16. UCB S.A.
13.16.1.
Company Details
13.16.2.
Company Overview
13.16.3.
Product Offerings
13.16.4.
Key Developments
13.16.5.
Financial Analysis
13.16.6.
SWOT Analysis
13.16.7.
Business Strategies
13.17. Xian Janssen Pharmaceutical Ltd
13.17.1. Company Details
13.17.2. Company Overview
13.17.3. Product Offerings
13.17.4. Key Developments
13.17.5. Financial Analysis
13.17.6. SWOT Analysis
13.17.7. Business Strategies
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
Reach to us
Call us on
+91-74002-42424
Drop us an email at
sales@absolutemarketsinsights.com
Why Absolute Markets Insights?
An effective strategy is the entity that influences a business to stand out of the crowd. An organization with a phenomenal strategy for success dependably has the edge over the rivals in the market. It offers the organizations a head start in planning their strategy. Absolute Market Insights is the new initiation in the industry that will furnish you with the lead your business needs. Absolute Market Insights is the best destination for your business intelligence and analytical solutions; essentially because our qualitative and quantitative sources of information are competent to give one-stop solutions. We inventively combine qualitative and quantitative research in accurate proportions to have the best report, which not only gives the most recent insights but also assists you to grow.